Bank of New York Mellon
AVXL icon

Bank of New York Mellon’s Anavex Life Sciences AVXL Stock Holding History

Bank of New York Mellon’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$746K Buy
288,199
+40,350
+16% +$119K ﹤0.01% 3530
2026
Q1 		$761K Buy
247,849
+3,794
+2% +$16.4K ﹤0.01% 3378
2025
Q4 		$869K Sell
244,055
-3,959
-2% -$24.3K ﹤0.01% 3322
2025
Q3 		$2.21M Buy
248,014
+16,518
+7% +$168K ﹤0.01% 2745
2025
Q2 		$2.13M Buy
231,496
+8,365
+4% +$71.4K ﹤0.01% 2709
2025
Q1 		$1.91M Buy
223,131
+2,882
+1% +$27.2K ﹤0.01% 2708
2024
Q4 		$2.37M Sell
220,249
-4,731
-2% -$36.4K ﹤0.01% 2692
2024
Q3 		$1.28M Sell
224,980
-55,576
-20% -$321K ﹤0.01% 2999
2024
Q2 		$1.18M Buy
280,556
+40,895
+17% +$165K ﹤0.01% 3097
2024
Q1 		$1.22M Sell
239,661
-16,437
-6% -$92.5K ﹤0.01% 3042
2023
Q4 		$2.38M Sell
256,098
-1,602
-0.6% -$11K ﹤0.01% 2738
2023
Q3 		$1.69M Buy
257,700
+991
+0.4% +$7.89K ﹤0.01% 2903
2023
Q2 		$2.09M Buy
256,709
+2,186
+0.9% +$18.7K ﹤0.01% 2809
2023
Q1 		$2.18M Buy
254,523
+6,049
+2% +$60.4K ﹤0.01% 2759
2022
Q4 		$2.3M Buy
248,474
+577
+0.2% +$6.16K ﹤0.01% 2780
2022
Q3 		$2.56M Buy
247,897
+29,771
+14% +$314K ﹤0.01% 2677
2022
Q2 		$2.18M Sell
218,126
-8,616
-4% -$81.6K ﹤0.01% 2786
2022
Q1 		$2.79M Buy
226,742
+1,031
+0.5% +$12.7K ﹤0.01% 2751
2021
Q4 		$3.91M Buy
225,711
+8,235
+4% +$156K ﹤0.01% 2599
2021
Q3 		$3.9M Sell
217,476
-43,691
-17% -$870K ﹤0.01% 2609
2021
Q2 		$5.97M Buy
261,167
+56,344
+28% +$835K ﹤0.01% 2397
2021
Q1 		$3.06M Buy
204,823
+10,772
+6% +$118K ﹤0.01% 2670
2020
Q4 		$1.05M Buy
194,051
+30,263
+18% +$159K ﹤0.01% 3235
2020
Q3 		$745K Buy
163,788
+558
+0.3% +$2.4K ﹤0.01% 3288
2020
Q2 		$803K Buy
163,230
+3,168
+2% +$12K ﹤0.01% 3226
2020
Q1 		$505K Buy
160,062
+17,951
+13% +$62.5K ﹤0.01% 3367
2019
Q4 		$368K Buy
142,111
+8,329
+6% +$21.9K ﹤0.01% 3724
2019
Q3 		$423K Buy
133,782
+393
+0.3% +$1.13K ﹤0.01% 3632
2019
Q2 		$449K Buy
133,389
+104,372
+360% +$324K ﹤0.01% 3652
2019
Q1 		$89K Sell
29,017
-841
-3% -$2.01K ﹤0.01% 4019
2018
Q4 		$47K Hold
29,858
– – ﹤0.01% 4065
2018
Q3 		$82K Sell
29,858
-1
-0% -$3 ﹤0.01% 4067
2018
Q2 		$78K Sell
29,859
-91,797
-75% -$256K ﹤0.01% 4034
2018
Q1 		$337K Sell
121,656
-56,282
-32% -$159K ﹤0.01% 3755
2017
Q4 		$573K Buy
177,938
+66,931
+60% +$263K ﹤0.01% 3562
2017
Q3 		$459K Sell
111,007
-242
-0.2% -$1.08K ﹤0.01% 3619
2017
Q2 		$593K Sell
111,249
-631
-0.6% -$3.65K ﹤0.01% 3525
2017
Q1 		$642K Buy
111,880
+5,826
+5% +$30.1K ﹤0.01% 3454
2016
Q4 		$420K Sell
106,054
-10,980
-9% -$39.1K ﹤0.01% 3659
2016
Q3 		$425K Sell
117,034
-12,242
-9% -$51.5K ﹤0.01% 3614
2016
Q2 		$790K Buy
129,276
+74,682
+137% +$361K ﹤0.01% 3293
2016
Q1 		$268K Buy
54,594
+10,395
+24% +$45.7K ﹤0.01% 3682
2015
Q4 		$246K Buy
+44,199
New +$314K ﹤0.01% 3798

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
AC
Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return

Bank of New York Mellon's AVXL Position: Q2 2026 in Review

Bank of New York Mellon increased its Anavex Life Sciences (AVXL) stake by 16% in Q2 2026, buying an estimated $119K and bringing the position to 288,199 shares worth $746K. The position accounts for ﹤0.01% of the portfolio, ranked #3530.

Bank of New York Mellon first reported a position in AVXL in Q4 2015 and has held it in 43 quarters since. The position peaked at $5.97M in Q2 2021. 79 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Bank of New York Mellon held 288,199 shares of Anavex Life Sciences worth $746K as of Q2 2026.
  • Bank of New York Mellon bought 40,350 Anavex Life Sciences shares in Q2 2026, an estimated $119K.
  • Anavex Life Sciences made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3530 holding.
  • Bank of New York Mellon first reported a position in Anavex Life Sciences in Q4 2015 and has held it in 43 quarters since.
  • Bank of New York Mellon's Anavex Life Sciences position peaked at $5.97M in Q2 2021.
  • 79 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.